Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefaclor Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefaclor Anhydrous SCHEMBL49912 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL33540 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8626211 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8524989 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8943624 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL16072812 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8478823 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL1006419 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL8626208 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E | |
| Cefaclor Anhydrous SCHEMBL27281884 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352691-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-11-21 | — | — | US | disclosed |
| EP-2528589-B1 | STABLE EFERVESCENT FORMULATIONS COMPRISING CEFACLOR | BILGIC MAHMUT (TR) | 2017-08-16 | — | — | EP | disclosed |
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160319322-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-11-03 | — | — | US | disclosed |
| EP-2181330-B2 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2016-08-31 | — | — | EP | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| EP-0523585-B1 | Improvements in or relating to beta lactam production | SANDOZ AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1043978-B1 | PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE | IDEXX LAB INC (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6423338-B1 | PHOSPHATIDES AND MICROCRYSTALS | IDEXX PHARMACEUTICALS, INC. | 2002-07-23 | — | — | US | disclosed |
| US-6180136-B1 | USEFUL FOR TREATING RESPIRATORY DISEASES, INFECTIONS, INFLAMMATION, AND PAIN IN VARIETY OF MAMMALS; ALSO ABLE TO SHARPLY REDUCE TOXICITY OF DRUG COMPOUNDS | IDEXX LABORATORIES, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-1043978-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE | IDEXX LABORATORIES, INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-2000027369-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS FOR THE SUSTAINED RELEASE OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR MANUFACTURE AND USE | IDEXX LABORATORIES, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| US-5608055-A | Beta lactam production | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1997-03-04 | — | — | US | disclosed |
| EP-0523585-A2 | Improvements in or relating to beta lactam production | BIOCHEMIE Gesellschaft m.b.H. (AT) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | HAMP, SLC40A1, FTH1 | ALDH1A1 4009/4885HSD17B10 1192/4885MAPT 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.